ArticleFrontiers in oncology2021
Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Establishment and validation of a 28-day clinical outcome prediction model for acute promyelocytic leukemia based on an early platelet-coagulation factor combined transfusion strategy.American journal of cancer research · 2026Article
- Risk factors and management strategies in acute promyelocytic leukemia: a real-world single-center retrospective study.Frontiers in medicine · 2026Article
- Predictors of Early Death in Acute Promyelocytic Leukemia.Medical sciences (Basel, Switzerland) · 2025Review
- Clinical characteristics and outcome of pediatric patients with high-risk acute promyelocytic leukemia, with special focus on risk factors of early death.Annals of hematology · 2025Article
- Thromboembolism in adult patients with acute promyelocytic leukemia: clinical characteristics, risk factors, and a predictive nomogram.Annals of hematology · 2025Article
- Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.European journal of haematology · 2025Article
- Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.International journal of hematology · 2024Review
- Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU.Scientific reports · 2024Article
- Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy.Cancers · 2024Review
- A global study for acute myeloid leukemia with RARG rearrangement.Blood advances · 2023Article
- The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage.International journal of hematology · 2023Article
- ATRA+ATO combination in APL - A commentary on "evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades" by Teng-Fei et al.Translational oncology · 2023Article
- Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.BMC cancer · 2023Article
- Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia.Frontiers in immunology · 2023Article
- Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades.Translational oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors at 20 institutions in 1 country.
Hong-Hu ZhuDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Ya-Fang MaDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Kang YuDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Hangzhou, China.
Gui-Fang OuyangDepartment of Hematology, Ningbo First Hospital, Ningbo, China.
Wen-Da LuoDepartment of Hematology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China.
Ren-Zhi PeiDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Wei-Qun XuDepartment of Hematology, The Children's Hospital Zhejiang University School of Medicine, Hangzhou, China.
Hui-Xian HuDepartment of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Shu-Ping MoDepartment of Hematology, The Affiliated Hospital of Jiaxing University, Jiaxing, China.
Xiao-Hua XuDepartment of Hematology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
Jian-Ping LanDepartment of Hematology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Jian-Ping ShenDepartment of Hematology, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China.
Li-Hong ShouDepartment of Hematology, Huzhou Central Hospital, Huzhou, China.
Shen-Xian QianDepartment of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wei-Ying FengDepartment of Hematology, Shaoxing People's Hospital, Wenzhou, China.
Pu ZhaoDepartment of Hematology, Ruian People's Hospital, Wenzhou, China.
Jin-Hong JiangDepartment of Hematology, Lishui City People's Hospital, Lishui, China.
Bei-Li HuDepartment of Hematology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Jin ZhangDepartment of Hematology, Sir Run Run Shaw Hospital (SRRSH) Affiliated with the Zhejiang University School of Medicine, Hangzhou, China.
Su-Ying QianDepartment of Hematology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Gong-Qiang WuDepartment of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Jinhua, China.
Wen-Ping WuDepartment of Hematology, People's Hospital of Quzhou, Quzhou, China.
Lei QiuDepartment of Hematology, Zhoushan Hospital, Zhoushan, China.
Lin-Jie LiDepartment of Hematology, Lishui Municipal Central Hospital, Jinhua, China.
Xiang-Hua LangDepartment of Hematology, The First People's Hospital of Yongkang, Jinhua, China.
Sai ChenDepartment of Hematology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Li-Li ChenDepartment of Hematology and Oncology, Taizhou First People's Hospital (Huangyan Hospital of Wenzhou Medical University), Taizhou, China.
Jun-Bin GuoDepartment of Hematology and Oncology, The First People's Hospital of Wenling, Taizhou, China.
Li-Hong CaoDepartment of Hematology, Shulan Hospital, Hangzhou, China.
Hui-Fang JiangDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Yong-Ming XiaDepartment of Hematology, Rheumatology and Nephrology, Yuyao People's Hospital, Ningbo University Yangming Affiliated Hospital, Ningbo, China.
Jing LeDepartment of Hematology and Oncology, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
Jian-Zhi ZhaoDepartment of Hematology, Shaoxing Central Hospital, Shaoxing, China.
Jian HuangDepartment of Hematology, The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, China.
Yue-Feng ZhangDepartment of Hematology, The First People's Hospital of Yuhang District, Hangzhou, China.
Ya-Li LvDepartment of Hematology, Xinchang People's Hospital, Shaoxing, China.
Jing-Sheng HuaDepartment of Hematology and Oncology, Taizhou Municipal Hospital, Taizhou, China.
Yong-Wei HongDepartment of Hematology, Ningbo Yinzhou No. 2 Hospital, Ningbo, China.
Cui-Ping ZhengDepartment of Hematotherapeutic, Wenzhou Central Hospital Medical Group, Wenzhou, China.
Ju-Xiang WangDepartment of Hematology and Oncology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Bin-Fei HuDepartment of Pediatric Hematology, Ningbo Women and Children's Hospital, Ningbo, China.
Xiao-Hui ChenDepartment of Hematology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
Li-Ming ZhangDepartment of Hematology, Zhuji People's Hospital, Shaoxing, China.
Shi TaoDepartment of Hematology, Shaoxing Second Hospital, Shaoxing, China.
Bing-Shou XieDepartment of Hematology, Wenzhou People's Hospital, Wenzhou, China.
Yue-Min KuangDepartment of Hematology, Jinhua People's Hospital, Jinhua, China.
Wen-Ji LuoDepartment of Hematology, The First People's Hospital of Xiaoshan District, Hangzhou, China.
Ping SuDepartment of Hematology, Zhejiang Xiaoshan Hospital, Hangzhou, China.
Jun GuoDepartment of Hematology and Oncology, The Sencond Affiliated Hospital of Zhejiang University, SAHZU Changxing Branch, Huzhou, China.
Xiao WuDepartment of Oncology and Hematology, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
Wei JiangDepartment of Hematology, Shangyu People's Hospital, Shaoxing, China.
Hui-Qi ZhangDepartment of Hematology, The First People's Hospital of Huzhou, Huzhou, China.
Yun ZhangDepartment of Hematotherapeutic, Yueqing People's Hospital, Wenzhou, China.
Chun-Mei ChenDepartment of Hematotherapeutic, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Xiao-Feng XuDepartment of Oncology and Hematology, Hangzhou Red Cross Hospital, Hangzhou, China.
Yan GuoDepartment of Hematology, The First People's Hospital of Pinghu, Jiaxing, China.
Jin-Ming TuDepartment of Gastroenterology and Hematology, Longyou People's Hospital, Quzhou, China.
Shao HuDepartment of Hematology and Oncology, The First Hospital of Ninghai County, Ningbo, China.
Xiao-Yan YanDepartment of Biostatistics, Peking University Clinical Research Institute, Beijing, China.
Chen YaoDepartment of Biostatistics, Peking University Clinical Research Institute, Beijing, China.
Yin-Jun LouDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
APL Cooperative Group of Zhejiang Province
Zhejiang University · CNShaoxing People's Hospital · CNJiaxing University · CNNingbo University · CNSecond Affiliated Hospital of Zhejiang University · CNThe First People's Hospital of Xiaoshan District, Hangzhou · CNPeking University · CNQuzhou City People's Hospital · CNWenzhou Medical University · CNYueqing People's Hospital · CNAffiliated Hospital of Hangzhou Normal University · CNChildren's Hospital of Zhejiang University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNFirst Hospital of Jiaxing · CNHangzhou First People's Hospital · CNHuzhou Central Hospital · CNJinhua Academy of Agricultural Sciences · CNJining First People's Hospital · CNLishui City People's Hospital · CNNingbo First Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most randomized trials for acute promyelocytic leukemia (APL) have investigated highly selected patients under idealized conditions, and the findings need to be validated in the real world. We conducted a population-based study of all APL patients in Zhejiang Province, China, with a total population of 82 million people, to assess the generalization of all-trans retinoic acid (ATRA) and arsenic as front-line treatment. The outcomes of APL patients were also analyzed. Between January 2015 and December 2019, 1,233 eligible patients were included in the final analysis. The rate of ATRA and arsenic as front-line treatment increased steadily from 66.2% in 2015 to 83.3% in 2019, with no difference among the size of the center (≥5 or <5 patients per year,
Indexed as
acute promyelocytic leukemiaarsenicATRAearly deathsurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.